Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem, a small-cap chemicals company, has hit a new 52-week low amid significant volatility, underperforming its sector. The stock has fallen consecutively over two days and is trading below multiple moving averages, reflecting ongoing challenges. Over the past year, it has declined notably compared to the Sensex.

Tatva Chintan Pharma Chem has faced notable volatility, with a significant decline in its stock price, trading near its 52-week low. The company has consistently underperformed against its moving averages and the broader market, reflecting challenges within the chemicals sector and a substantial drop over the past month.

Tatva Chintan Pharma Chem's stock rebounded significantly on February 13, 2025, after five days of decline. The company demonstrated high intraday volatility and outperformed its sector. Despite the recent surge, the stock remains below several key moving averages and has declined over the past month.

Tatva Chintan Pharma Chem has faced significant volatility, hitting a new 52-week low of Rs. 709.15. The stock has declined 10.01% over the past five days and 43.22% over the past year, underperforming its sector and trading below key moving averages amid ongoing market pressures.

Tatva Chintan Pharma Chem has faced notable volatility, hitting a new 52-week low and experiencing a cumulative loss over the past four days. Despite underperforming over the past year, the stock slightly outperformed its sector today, with trading activity showing limited fluctuations and a persistent bearish trend.

Tatva Chintan Pharma Chem has faced significant volatility, hitting a new 52-week low and experiencing a consecutive decline over the past three days. The stock is trading below all major moving averages and has seen a substantial year-over-year decline, contrasting with broader market gains.

Tatva Chintan Pharma Chem has faced significant volatility, hitting a new 52-week low and experiencing a notable decline over the past year. The company's stock has underperformed its sector and is trading below key moving averages, highlighting ongoing challenges in the chemicals industry.

Tatva Chintan Pharma Chem has reached a new 52-week low, reflecting a challenging year with a notable decline compared to the broader market. Despite recent volatility, the stock showed some recovery during the trading session, although it remains below key moving averages, indicating ongoing market challenges.

Tatva Chintan Pharma Chem has reached a new 52-week low, reflecting a challenging year with a notable decline compared to the broader market. Despite recent volatility, the stock showed some recovery during the trading session, although it remains below key moving averages, indicating ongoing market challenges.

Tatva Chintan Pharma Chem has reached a new 52-week low, reflecting a challenging year with a notable decline compared to the broader market. Despite recent volatility, the stock showed some recovery during the trading session, although it remains below key moving averages, indicating ongoing market challenges.

Tatva Chintan Pharma Chem has reached a new 52-week low, reflecting a significant decline and underperformance compared to its sector. The stock has been on a downward trend for four days but showed signs of recovery today. Its performance over the past year has been notably challenging.

Tatva Chintan Pharma Chem has faced significant volatility, reaching a new 52-week low and experiencing a consecutive decline over the past four days. The stock has underperformed its sector and is trading below multiple moving averages, indicating ongoing challenges in the market. Its performance over the past year shows a notable decrease.

Tatva Chintan Pharma Chem has faced significant volatility, reaching a new 52-week low and experiencing a consecutive decline over the past four days. The stock has underperformed its sector and is trading below multiple moving averages, indicating ongoing challenges in the market. Its performance over the past year shows a notable decrease.

Tatva Chintan Pharma Chem has faced significant volatility, reaching a new 52-week low and experiencing a consecutive decline over the past four days. The stock has underperformed its sector and is trading below multiple moving averages, indicating ongoing challenges in the market. Its performance over the past year shows a notable decrease.

Tatva Chintan Pharma Chem has reported negative financial results for the quarter ending January 2025. Despite this, the company's evaluation score has improved from -20 to -11 over the past three months, indicating a potential shift in its financial health and market positioning within the chemicals industry.

Tatva Chintan Pharma Chem has seen a revision in its score following a significant gain in its stock performance. The company outperformed its sector and demonstrated a notable trend reversal after previous declines. Additionally, it has been added to MarketsMOJO's list, reflecting its improved market position and performance indicators.

Tatva Chintan Pharma Chem, a smallcap company in the chemicals industry, saw a 7.45% increase in its stock price on November 7, 2024, outperforming the sector by 7.35%. However, according to MarketsMOJO, the stock is currently rated as a 'Strong Sell', indicating caution for investors. The stock has been on a positive streak for the last 3 days and is currently trading higher than its short-term moving averages. Despite market fluctuations, the company has maintained a strong performance.

Tatva Chintan Pharma Chem, a smallcap chemicals company, has hit a 52-week low and received a 'Strong Sell' rating from MarketsMOJO. The stock has been on a downward trend, underperforming the sector by -13.12%. Its disappointing performance in the past year and bearish trend suggest caution for investors and thorough research before investing.

Tatva Chintan Pharma Chem, a smallcap chemical company, has been experiencing a downward trend in its stock performance. On October 28, 2024, the stock lost -10.52% and hit a new 52-week and all-time low. It has also underperformed the sector and is currently trading below its moving averages. In comparison to the Sensex, the stock has shown a significant decline in the past month. Investors and experts are advised to closely monitor the company's financials and market trends before making any decisions.